新型生物制剂在 MG 的长程管理中有哪些优势?

参考文献：

[1]. 崔慧慧,徐梓桐,王金萍,等. 重症肌无力生物靶向药物治疗研究进展[J]. 兰州大学学报（医学版）,2023,49(12):88-94. 

[2]. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study [published correction appears in Lancet Neurol. 2017 Dec;16(12):954. 

[3]. Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395-406. 

[4]. 艾加莫德 a 注射液说明书.核准日期 2023 年 6 月 30 日

[5]. Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet Neurol. 2021 Aug;20(8):e5. 

[6]. 中国免疫学会神经免疫分会. 中国重症肌无力诊断和治疗指南(2020 版)[J]. 中国神经免疫学和神经病学杂志,2021,28(1):1-12. 

[7]. Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017;56(2):185-196.